302 related articles for article (PubMed ID: 32434511)
1. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
2. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
3. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
4. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
[TBL] [Abstract][Full Text] [Related]
5. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
[TBL] [Abstract][Full Text] [Related]
6. Overactive bladder medication: Anticholinergics versus mirabegron by specialty.
Sripad AA; Raker CA; Sung VW
Urologia; 2022 Nov; 89(4):511-516. PubMed ID: 35195050
[TBL] [Abstract][Full Text] [Related]
7. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
8. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
9. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
[TBL] [Abstract][Full Text] [Related]
10. Primary Nonadherence to Overactive Bladder Medications in an Integrated Managed Care Health Care System.
Rashid N; Vassilakis M; Lin KJ; Kristy R; Ng DB
J Manag Care Spec Pharm; 2017 Apr; 23(4):484-493. PubMed ID: 28345439
[TBL] [Abstract][Full Text] [Related]
11. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
12. Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review.
Duperrouzel C; Martin C; Mendell A; Bourque M; Carrera A; Mack A; Nesheim J
J Comp Eff Res; 2022 Dec; 11(18):1375-1394. PubMed ID: 36354285
[No Abstract] [Full Text] [Related]
13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
15. Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study.
Chung SD; Weng SS; Huang CY; Lin HC; Kao LT
J Clin Pharmacol; 2017 Aug; 57(8):1064-1070. PubMed ID: 28378881
[TBL] [Abstract][Full Text] [Related]
16. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
[TBL] [Abstract][Full Text] [Related]
17. No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study.
Kao LT; Huang CY; Lin HC; Chu CM
J Clin Pharmacol; 2018 Jun; 58(6):727-732. PubMed ID: 29315618
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care.
Odeyemi IA; Dakin HA; O'Donnell RA; Warner J; Jacobs A; Dasgupta P
Int J Clin Pract; 2006 Aug; 60(8):949-58. PubMed ID: 16893437
[TBL] [Abstract][Full Text] [Related]
20. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.
Suehs BT; Caplan EO; Hayden J; Ng DB; Gaddy RR
Drugs Aging; 2019 Oct; 36(10):957-967. PubMed ID: 31359329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
